Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus Trial for HHT
NCT04646356Phase 2Completed
- Sponsor
- Unity Health Toronto
- Start
- Oct 2020
- Primary completion
- Jan 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tacrolimus + Wuzhi capsule in hereditary hemorrhagic telangiectasia (HHT), sponsored by Unity Health Toronto. Primary endpoint: Change in epistaxis severity at 96 weeks. Started Oct 2020; status: completed.
02
Drugs
tacrolimus + Wuzhi capsule
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NCT04646356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04646356.